ID28783A - Komposisi farmasi untuk pelepasan termodifikasi dari pemeka insulin dan zat antidiabetes lain - Google Patents

Komposisi farmasi untuk pelepasan termodifikasi dari pemeka insulin dan zat antidiabetes lain

Info

Publication number: ID28783A
Authority: ID; Indonesia
Prior art keywords: pemeka; modificated; antidiabetes; insulin; release
Prior art date: 1998-11-12

Application number

IDW00200101045A

Other languages

English (en)

Indonesian (id)

Inventor

Karen Lewis

Nicola Jayne Lilliott

Donald Colin Mackenzie

Vincenzo Re

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-12

Filing date

1999-11-08

Publication date

2001-07-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID28783(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-11-12 Priority claimed from GBGB9824867.7A external-priority patent/GB9824867D0/en

1998-11-12 Priority claimed from GBGB9824866.9A external-priority patent/GB9824866D0/en

1998-11-12 Priority claimed from GBGB9824869.3A external-priority patent/GB9824869D0/en

1999-05-25 Priority claimed from GBGB9912190.7A external-priority patent/GB9912190D0/en

1999-05-25 Priority claimed from GBGB9912191.5A external-priority patent/GB9912191D0/en

1999-05-25 Priority claimed from GBGB9912193.1A external-priority patent/GB9912193D0/en

1999-11-08 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2001-07-05 Publication of ID28783A publication Critical patent/ID28783A/id

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

IDW00200101045A 1998-11-12 1999-11-08 Komposisi farmasi untuk pelepasan termodifikasi dari pemeka insulin dan zat antidiabetes lain ID28783A (id)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
GBGB9824867.7A GB9824867D0 (en)	1998-11-12	1998-11-12	Novel composition and use
GBGB9824866.9A GB9824866D0 (en)	1998-11-12	1998-11-12	Novel composition and use
GBGB9824869.3A GB9824869D0 (en)	1998-11-12	1998-11-12	Novel composition and use
GBGB9912190.7A GB9912190D0 (en)	1999-05-25	1999-05-25	Novel composition and use
GBGB9912191.5A GB9912191D0 (en)	1999-05-25	1999-05-25	Novel composition and use
GBGB9912193.1A GB9912193D0 (en)	1999-05-25	1999-05-25	Novel composition and use

Publications (1)

Publication Number	Publication Date
ID28783A true ID28783A (id)	2001-07-05

Family

ID=27547326

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IDW00200101045A ID28783A (id)	1998-11-12	1999-11-08	Komposisi farmasi untuk pelepasan termodifikasi dari pemeka insulin dan zat antidiabetes lain

Country Status (36)

Country	Link
EP (3)	EP1813273A1 (fr)
JP (1)	JP2002529504A (fr)
KR (1)	KR100643833B1 (fr)
CN (1)	CN1230162C (fr)
AR (1)	AR024228A1 (fr)
AT (1)	ATE406889T1 (fr)
AU (1)	AU768994B2 (fr)
BG (2)	BG65351B1 (fr)
BR (1)	BR9915285A (fr)
CA (1)	CA2351058A1 (fr)
CY (1)	CY1108587T1 (fr)
CZ (1)	CZ20011629A3 (fr)
DE (1)	DE69939485D1 (fr)
DK (1)	DK1131070T3 (fr)
DZ (1)	DZ2936A1 (fr)
EA (2)	EA200601145A1 (fr)
ES (1)	ES2312221T3 (fr)
HK (1)	HK1040910B (fr)
HR (1)	HRP20010343B1 (fr)
HU (1)	HUP0104303A3 (fr)
ID (1)	ID28783A (fr)
IL (2)	IL143002A0 (fr)
MY (1)	MY124695A (fr)
NO (1)	NO20012303L (fr)
NZ (1)	NZ511614A (fr)
OA (1)	OA11677A (fr)
PE (1)	PE20001238A1 (fr)
PL (1)	PL347634A1 (fr)
PT (1)	PT1131070E (fr)
SI (1)	SI1131070T1 (fr)
SK (1)	SK287038B6 (fr)
TR (1)	TR200101333T2 (fr)
TW (2)	TW592694B (fr)
UY (1)	UY25799A1 (fr)
WO (1)	WO2000028989A1 (fr)
YU (1)	YU37301A (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6099862A (en) *	1998-08-31	2000-08-08	Andrx Corporation	Oral dosage form for the controlled release of a biguanide and sulfonylurea
MY125516A (en)	1999-11-16	2006-08-30	Smithkline Beecham Plc	Novel composition based on thiazolidinedione and metformin and use
AU2007201729B2 (en) *	1999-12-23	2010-02-25	Novartis Ag	Use of hypoglycemic agent for treating impaired glucose metabolism
HUP0600522A2 (en)	1999-12-23	2006-11-28	Novartis Ag	Use of hypoglycemic agent for treating impaired glucose metabolism
US6761901B1 (en) *	2000-05-02	2004-07-13	Enzrel Inc.	Liposome drug delivery
US8257744B2 (en) *	2000-07-07	2012-09-04	Laboratorios Farmacéuticos Rovi, S.A.	Pharmaceutical forms for the release of active compounds
FR2811227A1 (fr) *	2000-07-07	2002-01-11	Philippe Maincent	Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
JP2004531463A (ja) *	2000-11-03	2004-10-14	アンドルクスラブス，エルエルシー	徐放メトホルミン組成物
US6790459B1 (en)	2000-11-03	2004-09-14	Andrx Labs, Llc	Methods for treating diabetes via administration of controlled release metformin
US6866866B1 (en) *	2000-11-03	2005-03-15	Andrx Labs, Llc	Controlled release metformin compositions
FR2816840B1 (fr)	2000-11-17	2004-04-09	Flamel Tech Sa	Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US7964216B2 (en)	2001-01-12	2011-06-21	Sun Pharma Advanced Research Company Limited	Spaced drug delivery system
CA2441064A1 (fr) *	2001-03-16	2002-09-26	Andrx Corporation	Preparation de sulfonyluree a liberation controlee
FR2822069B1 (fr) *	2001-03-19	2003-06-20	Lipha	Composition pharmaceutique comprenant un compose stimulant la secretion d'insuline et un derive de thiazolidinedione et son utilisation pour la preparation de medicamments destines a traiter le diabete
JP2004534056A (ja) *	2001-06-08	2004-11-11	エンドーファーマシューティカルズ，インコーポレイティド	アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
AU2001273290B2 (en) *	2001-07-10	2004-10-07	Kos Life Sciences, Inc.	Core formulation comprising troglitazone and a biguanide
GB0127805D0 (en) *	2001-11-20	2002-01-09	Smithkline Beecham Plc	Pharmaceutical composition
US7183321B2 (en)	2001-12-17	2007-02-27	Bristol-Myers Squibb Company	Antidiabetic formulation and method
US6824790B2 (en)	2002-01-09	2004-11-30	Enzrel Inc.	Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
MY139719A (en) *	2002-02-12	2009-10-30	Glaxo Group Ltd	Oral dosage form for controlled drug release
JP4732696B2 (ja)	2002-04-09	2011-07-27	フラメル・テクノロジー	活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
PL376577A1 (pl) *	2002-06-17	2006-01-09	Themis Laboratories Private Limited	Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
US7785627B2 (en)	2002-09-20	2010-08-31	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en)	2002-09-20	2015-06-23	Actavis, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en)	2002-09-20	2011-06-14	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en)	2002-09-20	2011-12-27	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
UA80991C2 (en)	2002-10-07	2007-11-26		Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
ES2645930T3 (es) *	2003-01-03	2017-12-11	Supernus Pharmaceuticals, Inc.	Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas
WO2004067001A1 (fr)	2003-01-29	2004-08-12	Takeda Pharmaceutical Company Limited	Procede pour realiser une preparation enrobee
AR045330A1 (es) *	2003-08-07	2005-10-26	Sb Pharmco Inc	Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GB0318824D0 (en) *	2003-08-11	2003-09-10	Glaxo Group Ltd	Novel composition
GB0320522D0 (en) *	2003-09-02	2003-10-01	Glaxo Group Ltd	Formulation
TWI339586B (en)	2003-10-31	2011-04-01	Takeda Chemical Industries Ltd	Solid preparation comprising pioglitazone or salt thereof,glimpiride and polyoxyethylene sorbitan fatty acid ester
US8263121B2 (en)	2004-04-14	2012-09-11	Takeda Pharmaceutical Company Limited	Solid pharmaceutical preparation
AU2004318976B2 (en) *	2004-04-29	2009-04-09	Lotus Pharmaceutical Co., Ltd.	Oral modified-release lozenges and their preparation method
CN1327840C (zh) *	2004-06-08	2007-07-25	天津药物研究院	一种药物组合物及其在制备用于治疗糖尿病中的应用
GB0502475D0 (en) *	2005-02-07	2005-03-16	Sb Pharmco Inc	Novel compositions
KR100657785B1 (ko) *	2005-02-19	2007-04-16	한국유나이티드제약 주식회사	글리메피리드, 메트포르민 및 은행엽엑스를 함유하는 약학적 조성물
US20060222709A1 (en) *	2005-03-18	2006-10-05	Agi Therapeutics Research Ltd.	Metformin methods and formulations for treating chronic constipation
MXPA05010977A (es) *	2005-10-12	2007-04-11	Abdala Leopoldo Espinosa	Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus.
MXPA05014092A (es) *	2005-12-20	2007-06-20	Leopoldo De Jesus Espinosa Abdala	Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2.
WO2007072992A2 (fr) *	2005-12-22	2007-06-28	Takeda Pharmaceutical Company Limited	Preparation solide
TW200816995A (en) *	2006-08-31	2008-04-16	Daiichi Sankyo Co Ltd	Pharmaceutical composition containing insulin sensitizers
KR100812538B1 (ko) *	2006-10-23	2008-03-11	한올제약주식회사	약물 제어방출형 메트포르민-글리메피리드 복합제제
US20100081672A1 (en) *	2006-12-07	2010-04-01	Schering Corporation	Ph sensitive matrix formulation
CA2678367C (fr) *	2007-03-02	2014-07-08	Farnam Companies, Inc.	Compositions a liberation prolongee utilisant des matieres cireuses
TW200906383A (en) *	2007-08-02	2009-02-16	Handok Pharmaceuticals Co Ltd	Sustained-release formulation comprising metformin acid salt
MX2010002695A (es)	2007-09-10	2010-04-01	Janssen Pharmaceutica Nv	Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt).
US8802156B2 (en)	2007-11-14	2014-08-12	Laboratorios Farmacéuticos Rovi, S.A.	Pharmaceutical forms for the release of active compounds
CN101548961B (zh) *	2008-04-03	2011-05-04	单宝华	一种治疗糖尿病及肥胖症的口服胶囊制剂
WO2010026467A2 (fr) *	2008-09-04	2010-03-11	Torrent Pharmaceuticals Ltd.	Forme pharmaceutique à libération prolongée de principe actif hautement soluble
US9056850B2 (en)	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
KR101189639B1 (ko) *	2008-12-15	2012-10-12	씨제이제일제당 (주)	메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
WO2011047113A1 (fr)	2009-10-14	2011-04-21	Janssen Pharmaceutica Nv	Procédé de préparation de composés utiles comme inhibiteurs de sglt2
NZ703128A (en)	2010-05-11	2016-04-29	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
CA2804506C (fr) *	2010-07-06	2018-08-21	Janssen Pharmaceutica Nv	Formulation pour le traitement par co-therapie du diabete
US9480663B2 (en)	2011-01-07	2016-11-01	Elcelyx Therapeutics, Inc.	Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en)	2011-01-07	2014-08-05	Elcelyx Therapeutics, Inc	Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en)	2011-01-07	2023-09-19	Anji Pharmaceuticals Inc.	Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en)	2011-01-07	2024-05-07	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
US9572784B2 (en)	2011-01-07	2017-02-21	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2012094636A2 (fr)	2011-01-07	2012-07-12	Elcelyx Therapeutics, Inc.	Traitements à base de ligand de récepteur chimiosensoriel
US9211263B2 (en)	2012-01-06	2015-12-15	Elcelyx Therapeutics, Inc.	Compositions and methods of treating metabolic disorders
WO2012140120A1 (fr)	2011-04-13	2012-10-18	Janssen Pharmaceutica Nv	Procédé de préparation de composés utiles en tant qu'inhibiteurs de sglt2
TWI542596B (zh)	2011-05-09	2016-07-21	健生藥品公司	（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
BR112014016808B1 (pt) *	2012-01-06	2022-01-11	Anji Pharma (Us) Llc	Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
CN104349773A (zh)	2012-01-06	2015-02-11	埃尔舍利克斯治疗公司	用于治疗代谢性病症的组合物和方法
CN102631332A (zh) *	2012-04-28	2012-08-15	邹立兴	一种伏格列波糖片剂及其制备方法
KR101409330B1 (ko) *	2012-05-11	2014-06-18	안국약품 주식회사	복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
EP2958548A1 (fr) *	2013-02-19	2015-12-30	Sanovel Ilac Sanayi ve Ticaret A.S.	Procédé de production de formulations de gliclazide
CA2970991C (fr) *	2014-12-17	2021-08-03	Goran Alderborn	Composition a liberation modifiee d'orlistat et d'acarbose pour le traitement d'obesite et de troubles metaboliques associes
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN105963280B (zh) *	2016-06-30	2018-11-06	合肥华方医药科技有限公司	一种伏格列波糖口腔速溶膜及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5522636A (en)	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
JPS5697277A (en)	1980-01-07	1981-08-05	Takeda Chem Ind Ltd	Thiazolidine derivative
US4538469A (en) *	1983-07-29	1985-09-03	Panametrics, Inc.	Integrated threshold arming method and apparatus
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
US4582839A (en)	1984-03-21	1986-04-15	Takeda Chemical Industries, Ltd.	2,4-thiazolidinediones
CN1003445B (zh)	1984-10-03	1989-03-01	武田药品工业株式会社	噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da)	1985-02-26	2000-08-07	Sankyo Co	Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja)	1985-06-10	1994-01-05	武田薬品工業株式会社	チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en)	1986-07-24	1989-03-14	Takeda Chemical Industries, Ltd.	Method for producing thiazolidinedione derivatives
ATE186724T1 (de) *	1987-09-04	1999-12-15	Beecham Group Plc	Substituierte thiazolidindionderivate
US4791125A (en)	1987-12-02	1988-12-13	Pfizer Inc.	Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008651A1 (fr)	1988-03-08	1989-09-21	Pfizer Inc.	Derives de thiaxolidinedione hypoglycemiques
FI904414A7 (fi)	1988-03-08	1990-09-07	Pfizer	Tiatsolidiinidioni-hypoglykeemisesti vaikuttavat aineet
IL91398A (en) *	1988-08-30	1994-05-30	Pfizer	Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
WO1991007107A1 (fr)	1989-11-13	1991-05-30	Pfizer Inc.	Agents d'oxazolidinedione hypoglycemiques
JP2630016B2 (ja) *	1990-05-21	1997-07-16	ヤマハ株式会社	吹奏感付加器を有する電子管楽器
US5089514A (en)	1990-06-14	1992-02-18	Pfizer Inc.	3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
AU650465B2 (en)	1990-07-03	1994-06-23	Yamanouchi Pharmaceutical Co., Ltd.	Bisheterocyclic compound
FI930772L (fi)	1990-08-23	1993-02-22	Pfizer	Hydroxiureaderivat som saenker glugosnivao i blodet
JPH04210683A (ja)	1990-12-06	1992-07-31	Terumo Corp	チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5183823A (en)	1991-04-11	1993-02-02	Takeda Chemical Industries, Ltd.	Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
KR100249988B1 (ko)	1991-04-11	2000-04-01	로렌스 티. 마이젠헬더	티아졸리딘디온 유도체, 그의 제조방법 및 용도
US5502078A (en) *	1991-05-28	1996-03-26	Zeneca Limited	Chemical compounds
TW222626B (fr)	1991-07-22	1994-04-21	Pfizer
FR2680512B1 (fr)	1991-08-20	1995-01-20	Adir	Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja)	1992-03-26	1993-10-19	Japan Tobacco Inc	新規なトリアジン誘導体
US5264451A (en)	1992-04-07	1993-11-23	American Home Products Corporation	Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
AU3959193A (en)	1992-04-10	1993-11-18	Smithkline Beecham Plc	Heterocyclic compounds and their use in the treatment of type II-diabetes
WO1993022445A1 (fr)	1992-05-05	1993-11-11	The Upjohn Company	Procede de production de metabolites de pioglitazone
SK695A3 (en)	1992-07-03	1995-07-11	Smithkline Beecham Plc	Heterocyclic compounds method of their production and using
US5232945A (en)	1992-07-20	1993-08-03	Pfizer Inc.	3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en)	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
RU2071783C1 (ru) *	1993-09-07	1997-01-20	Ессентукский центральный военный санаторий	Способ получения средства для лечения сахарного диабета
US5457109A (en)	1993-09-15	1995-10-10	Warner-Lambert Company	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DE4432757A1 (de) *	1994-09-14	1996-03-21	Boehringer Mannheim Gmbh	Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TW438587B (en) *	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
GB9619757D0 (en) *	1996-09-21	1996-11-06	Knoll Ag	Chemical process
RU2114617C1 (ru) *	1996-09-27	1998-07-10	Юрий Георгиевич Каминский	Антидиабетическое средство на основе янтарной кислоты
IL132032A0 (en) *	1997-03-24	2001-03-19	Galderma Res & Dev	Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus
GB9715295D0 (en) *	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment

1999
- 1999-11-08 WO PCT/EP1999/008704 patent/WO2000028989A1/fr not_active Ceased
- 1999-11-08 YU YU37301A patent/YU37301A/sh unknown
- 1999-11-08 DE DE69939485T patent/DE69939485D1/de not_active Expired - Lifetime
- 1999-11-08 DK DK99964483T patent/DK1131070T3/da active
- 1999-11-08 CZ CZ20011629A patent/CZ20011629A3/cs unknown
- 1999-11-08 ES ES99964483T patent/ES2312221T3/es not_active Expired - Lifetime
- 1999-11-08 EA EA200601145A patent/EA200601145A1/ru not_active IP Right Cessation
- 1999-11-08 EP EP07105992A patent/EP1813273A1/fr not_active Withdrawn
- 1999-11-08 PL PL99347634A patent/PL347634A1/xx not_active Application Discontinuation
- 1999-11-08 EP EP08163249A patent/EP1992337A1/fr not_active Withdrawn
- 1999-11-08 OA OA1200100117A patent/OA11677A/en unknown
- 1999-11-08 BR BR9915285-1A patent/BR9915285A/pt not_active Application Discontinuation
- 1999-11-08 PT PT99964483T patent/PT1131070E/pt unknown
- 1999-11-08 AT AT99964483T patent/ATE406889T1/de active
- 1999-11-08 HK HK02101023.7A patent/HK1040910B/en not_active IP Right Cessation
- 1999-11-08 HR HR20010343A patent/HRP20010343B1/xx not_active IP Right Cessation
- 1999-11-08 EP EP99964483A patent/EP1131070B1/fr not_active Revoked
- 1999-11-08 KR KR1020017005967A patent/KR100643833B1/ko not_active Expired - Fee Related
- 1999-11-08 TR TR2001/01333T patent/TR200101333T2/xx unknown
- 1999-11-08 SI SI9931017T patent/SI1131070T1/sl unknown
- 1999-11-08 IL IL14300299A patent/IL143002A0/xx unknown
- 1999-11-08 EA EA200100541A patent/EA007610B1/ru not_active IP Right Cessation
- 1999-11-08 AU AU30338/00A patent/AU768994B2/en not_active Ceased
- 1999-11-08 CA CA002351058A patent/CA2351058A1/fr not_active Abandoned
- 1999-11-08 NZ NZ511614A patent/NZ511614A/en not_active IP Right Cessation
- 1999-11-08 ID IDW00200101045A patent/ID28783A/id unknown
- 1999-11-08 SK SK644-2001A patent/SK287038B6/sk not_active IP Right Cessation
- 1999-11-08 CN CNB998154792A patent/CN1230162C/zh not_active Expired - Fee Related
- 1999-11-08 HU HU0104303A patent/HUP0104303A3/hu unknown
- 1999-11-08 JP JP2000582036A patent/JP2002529504A/ja not_active Ceased
- 1999-11-10 DZ DZ990236A patent/DZ2936A1/fr active
- 1999-11-10 AR ARP990105697A patent/AR024228A1/es unknown
- 1999-11-11 MY MYPI99004896A patent/MY124695A/en unknown
- 1999-11-12 PE PE1999001146A patent/PE20001238A1/es not_active Application Discontinuation
- 1999-11-12 UY UY25799A patent/UY25799A1/es not_active Application Discontinuation
- 1999-12-24 TW TW088122853A patent/TW592694B/zh not_active IP Right Cessation
- 1999-12-24 TW TW093109152A patent/TWI251487B/zh not_active IP Right Cessation
2001
- 2001-05-07 IL IL143002A patent/IL143002A/en not_active IP Right Cessation
- 2001-05-10 NO NO20012303A patent/NO20012303L/no not_active Application Discontinuation
- 2001-06-07 BG BG105568A patent/BG65351B1/bg unknown
- 2001-06-07 BG BG109852A patent/BG109852A/bg unknown
2008
- 2008-11-24 CY CY20081101346T patent/CY1108587T1/el unknown

Also Published As

Publication number	Publication date
IL143002A0 (en)	2002-04-21
NZ511614A (en)	2003-12-19
TR200101333T2 (tr)	2001-10-22
AU768994B2 (en)	2004-01-15
NO20012303L (no)	2001-07-04
EA011633B1 (ru)	2009-04-28
EP1131070A1 (fr)	2001-09-12
PT1131070E (pt)	2008-11-19
IL143002A (en)	2007-02-11
CA2351058A1 (fr)	2000-05-25
EA007610B1 (ru)	2006-12-29
DK1131070T3 (da)	2008-11-17
DZ2936A1 (fr)	2004-03-15
EA200601145A1 (ru)	2009-04-28
WO2000028989A1 (fr)	2000-05-25
CZ20011629A3 (cs)	2001-12-12
DE69939485D1 (de)	2008-10-16
EA200100541A1 (ru)	2001-10-22
PL347634A1 (en)	2002-04-22
YU37301A (sh)	2005-06-10
EP1813273A1 (fr)	2007-08-01
KR20010080419A (ko)	2001-08-22
SK6442001A3 (en)	2001-12-03
OA11677A (en)	2005-01-12
AU3033800A (en)	2000-06-05
BG65351B1 (bg)	2008-03-31
SK287038B6 (sk)	2009-10-07
HRP20010343B1 (hr)	2010-11-30
PE20001238A1 (es)	2001-01-11
CN1230162C (zh)	2005-12-07
KR100643833B1 (ko)	2006-11-10
ATE406889T1 (de)	2008-09-15
HK1040910B (en)	2009-06-26
ES2312221T3 (es)	2009-02-16
NO20012303D0 (no)	2001-05-10
TW592694B (en)	2004-06-21
HK1040910A1 (en)	2002-06-28
CY1108587T1 (el)	2014-04-09
EP1131070B1 (fr)	2008-09-03
BG105568A (en)	2002-01-31
HUP0104303A2 (hu)	2002-03-28
TW200418453A (en)	2004-10-01
CN1348369A (zh)	2002-05-08
EP1992337A1 (fr)	2008-11-19
BR9915285A (pt)	2001-08-07
SI1131070T1 (sl)	2008-12-31
AR024228A1 (es)	2002-09-25
UY25799A1 (es)	2000-12-29
TWI251487B (en)	2006-03-21
HUP0104303A3 (en)	2003-12-29
MY124695A (en)	2006-06-30
HRP20010343A2 (en)	2002-06-30
BG109852A (bg)	2008-11-28
JP2002529504A (ja)	2002-09-10

Publication	Publication Date	Title
ID27040A (id)	2001-02-22	Bentuk sediaan dengan pelepasan berpulsa dari bahan farmasi oral
ID22973A (id)	1999-12-23	Komposisi farmasi dari pemberian oral dari turunan n-piperidino-3-pirazolkarboksamida, garam-garam dan solvatnya
ID29994A (id)	2001-10-25	Komposisi farmasi untuk melawan ccr5 terdiri dari turunan anilida
NO2011010I1 (no)	2011-06-20	Naproksen- og esomeprazoltabletter med modifisert frisetting
ATE357941T1 (de)	2007-04-15	Vorrichtungen zur medikamentverabreichung
IS5248A (is)	1999-11-15	Lyfjasamsetningar sem innihalda vorikónasól
EE9700363A (et)	1998-06-15	Uus anesteseeriva toimega farmatseutiline segu
EE200000383A (et)	2001-12-17	Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
SI1131070T1 (sl)	2008-12-31	Farmacevtski sestavek za modificirano sproĺ äśanje senzibilizatorja za inzulin in metformina
TR199800743A3 (tr)	1999-10-21	Ispençiyari uygulamaya mahsus devamli salivermeli polimer karisim matrisi.
BR9713237B1 (pt)	2009-01-13	comprimido de liberaÇço controlada de cloridrato de alfuzosina e composiÇço farmacÊutica compreendendo o mesmo.
ID26639A (id)	2001-01-25	Sediaan farmasi yang mengandung agonis reseptor angiotensin ii jenis 2 dan pemakaiannya
NO20006630L (no)	2001-02-26	Farmasöytisk sammensetning for behandlingen av diabetes
DE69812089D1 (de)	2003-04-17	Pharmazeutische omeprazol-formulierung
DE60043305D1 (de)	2009-12-24	Pharmazeutische zubereitungen zur behandlung von insulinresitenz
DK1035833T3 (da)	2006-01-09	Sammensætning til nasal indgivelse
ID29350A (id)	2001-08-23	Komposisi farmasi untuk pelepasan terus menerus dan metode pelepasan zat aktif farmasi
DK1066049T3 (da)	2003-09-29	Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse
IL183972A0 (en)	2007-10-31	Pharmaceutical composition for modified release insulin sensitiser
IL156262A0 (en)	2004-01-04	Anti-cd28 antibodies having no mitogenic activity and pharmaceutical compositions containing the same
ECSP045171A (es)	2004-08-27	Régimen de dosificación y composición farmacéutica para anticoncepción de emergencia
NO20001375L (no)	2000-03-16	Legemiddelformulering med kontrollert virkestoffrigivning
PL374778A1 (en)	2005-10-31	Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
DK1474152T3 (da)	2007-04-10	Orodispergerbar farmaceutisk sammensætning omfattende ivabradin
EE03387B1 (et)	2001-04-16	Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks